Pfizer's COVID-19 Oral Drug Paxlovid Priced at RMB 2,300 per Box in China and Included in National Health Insurance

According to the latest report by Jing Shi News, Pfizer's COVID-19 oral medication, Paxlovid (a combination pack of Nirmatrelvir Tablets and Ritonavir Tablets), has now been put into use in Zhejiang, priced at 2,300 yuan per box and covered by medical insurance.

Previously, on February 12, Pfizer's oral small molecule coronavirus treatment drug Paxlovid was granted emergency approval in China.

On March 9, Pfizer announced a collaboration with Sinopharm. During the agreement period (2022), Sinopharm will be responsible for the commercial operations of Pfizer’s COVID-19 treatment drug, Nirmatrelvir Tablets/Ritonavir Tablets combination pack (Paxlovid), in the Chinese market.

On March 21, the National Healthcare Security Administration issued the "Notice on Effectively Carrying Out the Current Medical Security Work for Epidemic Prevention and Control." The notice mentioned timely adjustments to the inclusion of COVID-19 treatment drugs in the scope of medical insurance payments. For the newly added Paxlovid (Nirmatrelvir/Ritonavir) in the "Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9)," medical institutions will procure it at a price agreed upon by the company and relevant departments, and the healthcare security department will ensure payment as per regulations.

Source: PharmaCircle